SUTRO BIOPHARMA, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-38.5M | $-38.5M | $-56.9M | $-11.5M | $-76.0M | $-48.8M | $-48.0M | $-58.2M |
| Depreciation & Amortization | — | $1.3M | — | — | $1.9M | — | — | $1.8M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $1.6M | — | — | $5.5M | — | — | $6.1M |
| Net Cash from Operating Activities | $-38.3M | $-42.3M | $-38.2M | $-44.7M | $-67.9M | $-64.5M | $9.5M | $-64.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-45.3M | — | — | $-16.3M | — | — | $64.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $103.1M | — | — | $66.0K | — | — | $-3.4M |
| Net Change in Cash | — | $15.6M | — | — | $-84.1M | — | — | $-4.1M |
| Free Cash Flow | — | — | — | — | — | — | — | — |